# GLP-1 Spending: Lower for Medical Care, Higher Overall | Buy This GLP

A U.S. survey analysis found $6,483 higher total spending and $2,586 lower non-drug spending per person-year among sustained GLP-1 users.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/glp1-total-spending-with-the-drug
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Spending: Lower for Medical Care, Higher Overall

A U.S. survey linked sustained GLP-1 use to $2,586 lower non-drug spending and $6,483 higher total spending per person-year.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20263 min readUpdated November 2026

Same-year spending, per person-year · non-drug medical · −$2,586 · acute care · −$2,019 · total spending · +$6,483 · Adjusted differences from the survey model.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   An adjusted U.S. survey analysis found $6,483 higher total spending per person-year among sustained GLP-1 users.
-   The same model estimated $2,586 lower non-drug spending and $2,019 lower acute-care spending.
-   The study compared spending within a calendar year. It could neither establish cause nor measure longer-term savings.

A [separate claims study of semaglutide](https://buythisglp.com/research/semaglutide-medical-cost-saving-adherence) examined medical spending among people who stayed on treatment. In this survey, total spending included prescriptions [\[1\]](https://buythisglp.com/research/glp1-total-spending-with-the-drug#ref-1). Overall spending was higher despite lower adjusted non-drug spending.

## Who was included

The study used the U.S. Medical Expenditure Panel Survey. Its main analysis used 2019 and 2021, the two years with usable body mass index data. It included adults with obesity and at least one cardiometabolic risk factor [\[1\]](https://buythisglp.com/research/glp1-total-spending-with-the-drug#ref-1).

The primary analysis covered a sample of 7,144 person-year records. Of those, 275 involved sustained GLP-1 use. A person-year is a record of one person for one year. Using only that year limits what the analysis can say about future spending.

## How spending differed

Our [comparison of national GLP-1 spending studies](https://buythisglp.com/research/how-much-are-countries-spending-on-glp1-drugs) distinguishes drug spending from total medical spending. This study asks how overall spending differed between the groups it followed.

After adjustment, total spending was $6,483 higher per person-year. Non-drug spending was $2,586 lower. Acute care, which is part of non-drug spending, was $2,019 lower [\[1\]](https://buythisglp.com/research/glp1-total-spending-with-the-drug#ref-1).

Before adjustment, non-drug spending was higher in the GLP-1 group. The reversal shows how much the comparison depended on accounting for differences between groups. Unmeasured differences could still affect the estimates [\[1\]](https://buythisglp.com/research/glp1-total-spending-with-the-drug#ref-1).

## What it says about a household budget

For a personal budget, a [six-month cost estimate](https://buythisglp.com/tools/six-month-cost) uses the prices and fees someone actually pays.

The survey found no statistically clear difference in out-of-pocket spending [\[1\]](https://buythisglp.com/research/glp1-total-spending-with-the-drug#ref-1). Its total spending estimate cannot tell a cash buyer what they will pay.

## Frequently asked

Did GLP-1 users have lower total spending?

The adjusted estimate was $6,483 higher per person-year. The survey cannot establish whether the drug caused the difference.

How did spending outside the pharmacy differ?

Adjusted non-drug spending was $2,586 lower per person-year. Acute care, one component of that spending, was $2,019 lower.

What does the study say about long-term savings?

It measured spending within a calendar year. It cannot estimate savings or costs that accumulate over several years.

## Sources

1.  \[1\] Çelebi O, et al. (2026). GLP-1 Use, Downstream Medical Spending, and Acute-Care Burden Among Adults with BMI-Defined Obesity: An Overlap-Weighted MEPS Analysis Healthcare. [PMID 42588330](https://www.mdpi.com/2227-9032/14/15/2362)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
